SFI
ONCT

Susquehanna Fundamental Investments’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,135
Closed -$355K – 1817
2021
Q1 		$355K Buy
2,135
+1,535
+256% +$203K 0.01% 1251
2020
Q4 		$59K Buy
+600
New +$38K ﹤0.01% 1449

Other funds holding ONCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return

Susquehanna Fundamental Investments's ONCT Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2021, closing a stake of 2,135 shares — an estimated $355K sold.

Susquehanna Fundamental Investments first reported a position in ONCT in Q4 2020 and held it in 2 quarters. The position peaked at $355K in Q1 2021. 84 funds tracked by Wall St. Rank hold ONCT as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 2,135 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $355K.
  • Susquehanna Fundamental Investments first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Oncternal Therapeutics, Inc. Common Stock position peaked at $355K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.